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Intraoperative electron beam radiotherapy (IOERT) for prostate cancer (PC) is a radiotherapeutic technique, giving high doses
of radiation during radical prostatectomy (RP). This paper presents the published treatment approaches for intraoperative
radiotherapy analyzing functional outcome, morbidity, and oncological outcome in patients with clinical intermediate-high-risk
prostate cancer. A systematic review of the literature was performed, searching PubMed and Web of Science. A “free text” protocol
using the term intraoperative radiotherapy and prostate cancer was applied. Ten records were retrieved and analyzed including
more than 150 prostate cancer patients treated with IOERT. IOERT represents a feasible technique with acceptable surgical time
and minimal toxicity. A greater number of cases and longer follow-up time are needed in order to assess the long-term side eﬀects
and oncological outcome.
1.Introduction
The optimal treatment of locally advanced PC is still unclear
[1]. The use of radical prostatectomy (RP) alone is contro-
versial, and external beam radiation (EBRT) associated with
hormonal therapy (HT) has been the traditional treatment
modality for this stage of disease [2]. However, even with
the use of multimodal approaches, only a 37–62% and 44%
disease-free survival at 5 and 10 years can be obtained [3–7]
and side eﬀects of these treatments are not limited [2].
With the aim to improve the clinical outcomes of
locally advanced PC, various radiotherapeutic approaches
have been implemented. IOERT is being investigated as a
technique to deliver a high dose of radiation to a locally
advanced tumor protecting adjacent normal tissues at the
time of surgery. This new technique has been used for
treatment of several tumours as a boost or sole radiation
treatment before or after tumour resection with the aim
to improve local tumour control. Diﬀerent approaches and
diﬀerentacceleratorshavebeenused,asreportedintechnical
and dose-ﬁnding studies.
IOERT for PC was ﬁrst proposed in Japan more than
twenty years ago, either as a single treatment [8, 9]o r
combined with pelvic lymphadenectomy (PLND) or EBRT
to pelvic lymph nodes [10, 11]. Recently, three Italian
centers have reported series of intermediate and high-risk
PC patients treated with IOERT combined with RP and
PLND [12–14]. The potential advantage of IOERT is to
allow optimal targeting and identiﬁcation of the prostate
and surrounding structures. Recent radiobiological studies
suggest that the use of a single high fraction of radiation may
increase theeﬃcacy of the treatment leading to higher tumor
cell killing [15].
Theaimofthispaperistodescribethediﬀerenttechnical
approaches of IOERT and the available results in terms of
clinical outcome for locally advanced PC.
2.MaterialandMethods
A literature search was performed using PubMed and Web
of Science from 1975 to 2011. The keywords IOERT and2 Advances in Urology
Table 1: Treatment modality and outcomes of selected series of IORT in prostate cancer.






9 IORT(20–25Gy) + PNLD + EBRT(50Gy) ±
HT—without RP
100% 5y
— No severe toxicity
5 IORT(30–35Gy) + PNLD ± HT—without
RP 80% 5y No severe toxicity
Abe et al. [17]2 1
IORT (28–35Gy) single dose +
PNLD—without RP
IORT(20–25Gy) + EBRT(50Gy) ± HT
81% 5y 72% 100% hematuria
Kojima et al.
[10] 30 IORT(12–20Gy) + PRP/RRP ± PNLD +
EBRT ± HT — 43% —
Higashi et al.
[11] 35 PNLD + IORT(25–30Gy) + EBRT(30Gy) ±
HT—without RP — 92% (stage B) No severe toxicity
87% (stage C)
Saracino et al.
[12] 34 IORT(16–22Gy) + RRP ± PNLD + EBRT ±
HT 91% — No severe toxicity
Rocco et al. [19] 3 3 R R P+P N L D+I O R T ( 1 2G y )+E B R T± HT — — 1l y m p h o c e l e
3 anastomotic stricture
Krengli et al.
[14, 20] 38 RRP + PNLD + IORT(9–12Gy) + EBRT ±
HT ——
11% G2 GE toxicity
4% G2 GU toxicity
5l y m p h o c e l e
2p e l v i ch e m a t o m a
RP = radical prostatectomy, PRP = perineal radical prostatectomy, RRP = retropubic radical prostatectomy, PLND = pelvic lymphadenectomy, EBRT =
external-beam radiation, HT = hormonal therapy, GE = gastro-enteric, GU = genito-urinary.
PC were used. A free-text strategy was applied without
limitations. We retrieved 11 references dealing with IOERT
a n dP C( Table 1). Only phase I-II studies are available.
No randomized clinical trials (RCTs), systematic reviews of
cohort studies, and low-quality RCTs are reported. The aim
was not to produce a meta-analysis but to critically evaluate
and discuss the use of IOERT in the treatment of PC.
3. Result
The ﬁrst series of IOERT for PC was reported by the
Kyoto University and Saitama Cancer Center in Japan. The
authors initially carried out IOERT as single treatment or
in combination with PLND or EBRT to pelvic lymph nodes
[9–11, 16, 17]. Perineal approach without RP using electron
energy from 10 to 14Mev has been performed in 14 patients
by Takahashi et al. [9]. Five patients treated by IOERT alone
received single doses of 2800 to 3500cGy. Two patients
treated with 2800 and 3000cGy, respectively, had local
recurrence. A single dose of 2000 or 2500cGy was delivered
intraoperatively to 9 patients as a boost dose in conjunction
with external irradiation of 5000cGy for the treatment of
pelvic lymph nodes. All these patients achieved local control.
No patients in the overall series developed serious bladder,
urethral, or rectal complications. An update from the same
center reported a local control and 5-year survival rates of
81% and 72%, respectively, with 2% late toxicity consisting
of chronic cystitis and urethral stricture [17].
The experience of the Saitama Cancer Center began
with the perineal approach and switched to the retropubic
approach after the ﬁrst 10 cases, due to the potential risk
of rectal damage, impossible PNLD, and patient discomfort
[10, 11]. Radiation therapy included 25–30Gy of IOERT
on the prostate and 30Gy of external beam radiotherapy
to the small pelvic region. Most patients received additional
androgen ablation treatment. The authors reported 92% and
87% overall survival rates in 35 patients with stage B and
stage C disease, respectively, without severe side eﬀects.
More recently, Italian authors reported phase I-II studies
with a relatively higher number of patients compared with
the Japanese series [12–14, 18, 19].
Ad i ﬀerent treatment approach was adopted by three
Italian centers. In Saracino’s series, 34 patients with localized
PCwithonlyonehigh-riskfactor(Gleasonscore ≥7,clinical
stage ≥ T2c, or prostate-speciﬁc antigen of 11–20ng/mL)
and without clinical evidence of lymph node metastases were
treated with RP and IOERT on the tumor bed. Dose levels of
16, 18, and 20Gy were selected [12]. The IOERT procedure
was performed after prostate removal and at the end of
bladder-urethral anastomosis. Negative frozen section of
bilateral obturator nodes was mandatory. In vivo dosimetry
wasperformedbyMOSFETdosimetersinsertedinrectaland
urethral catheters in order to obtain a reliable dosimetry at
the level of the bladder-urethral anastomosis [18].
After a median follow-up of 41 months, the authors
reported a local control rate of 91% with biochemical-
failure-free survival at 3 years of 77%. They did not observe
any relevant early or late toxicity. In this series, unfavorable
prognostic factors were stage >T3, PSA > 10ng/mL at
univariate analysis, and surgical positive margins at both
univariateandmultivariateanalyses.Ofnote,postsurgicalT2
stage was detected in 53% of cases [12].Advances in Urology 3
Figure 1: The appropriate collimator is placed and beam energy is
chosen in order to include the prostate gland and the surrounding
soft tissues with a suitable margin of 0.5–1 cm.
Orecchia et al. and Krengli et al. reported on 11 and
38 patients, respectively, treated in a similar fashion as in
Saracino’s study but before prostate removal. In these series,
IOERT was not used as a single radiation treatment modality
but as an anticipated boost followed by postoperative EBRT
according to the pathological ﬁndings. A dose of 10–12Gy
was prescribed to the 90% isodose using 9–12MeV IOERT
[13, 14]. In these two series, surgery is performed with
a median abdominal incision to approach the retropubic
space. The pelvic fascia is prepared and the anterior face of
the prostate exposed. Puboprostatic ligaments are sectioned
and the deep dorsal vein plexus controlled. The apex of
the prostate and the endopelvic urethra are visualized. A
stitch is placed as a marker of the bladder neck. The
anterior-posterior prostate diameter and the distance from
prostate surface to the anterior rectal wall are measured by
intraoperative ultrasound. Based on clinical and ultrasound
parameters, the appropriate collimator and beam energy
are chosen in order to include the prostate gland and the
surrounding soft tissues with a suitable margin of 0.5–
1cm Figures 1 and 2. Orecchia et al. administered IORT
using a Liac (Info and Tech, Rome, Italy) mobile linear
accelerator, while Krengli et al. used a dedicated linear
accelerator (Mobetron, Intraop, Sunnyvale, CA) installed in
theoperatingroom,deliveringelectronbeamsof9to12MeV
forat otald oseof12G y(Figure 3).Rectaldosewasmeasured
“in vivo” by radio-chromic ﬁlms placed on the surface of a
rectal probe. Three-dimensional conformal RT was delivered
3 months after surgery using 4 to 6 customized beams for a
total dose of 46–50Gy in 25 fractions (2Gy/fraction) in case
of extracapsular extension and/or positive surgical margins
at pathology. Adjuvant HT was recommended for 2 years in
presence of pT3b-T4 disease or positive lymph nodes (LN+).
In case of biochemical failure permanent HT was given [14].
In 2009 Rocco et al. reported an update of their series,
comparing in a matched-pair analysis 33 high-risk patients
treated by IOERT with a historical group of 100 patients who
underwent RP and adjuvant RT and HT [19]. After a median
follow-up of 16 months, only 1 of 33 patients experienced
biochemical failure. Surgical outcome was equivalent in
the two groups, whereas the urinary continence rate was
lightly worse in the IOERT group. However, the continence
Figure 2: The collimator is ﬁxed to the operating table.
Figure 3: Dedicated linear accelerator (Mobetron, Intraop, Sunny-
vale, CA) installed in the operating room.
improved similarly over time in both patient groups. Post-
surgical T2 stage was detected in 36% of cases, while most
cases were classiﬁed as pT3 [19].
The series by Krengli et al. was updated in terms of
patient number and clinical outcome in 2010 [20]. After a
median follow-up of 24 months, all patients were alive and
18% experienced biochemical failure with median time to
progression of 27 months (range 6–44). Toxicity and surgical
complicationrateswerelow.Complicationsmainlyconsisted
of lymphoceles (16%) and pelvic hematomas (6%). Eighty-
four percent of patients were fully continent, and no grade
3-4 late toxicity was observed. Postsurgical T2 stage was
detected in 37% of cases, and most cases were pT3.
4. Discussion
Optimal treatment strategy for locally advanced PC remains
unknown. Local control after RP depends on Gleason score,
preoperative PSA level, pathological stage, and margins
status [21].
Multimodal approach which includes adjuvant HT or
RT after RP clearly improves the outcomes in men with
locally advanced PC [22, 23]. The rationale of IOERT in
locally advanced PC is based on the unsatisfactory results
obtained by other treatment modalities [24]. Using IOERT,
it is possible to irradiate the whole surgical bed, including
the tissues surrounding the prostate with a limited dose to
the rectum.4 Advances in Urology
IOERT dose of 12Gy at the 90% isodose compared
to doses delivered with conventional EBRT fractionation is
similar to the normalized dose of 56.2Gy with an alpha/beta
ratio of 1.5Gy. The mean dose delivered to the prostate bed
of 8.7Gy reported by Orecchia et al. [13] corresponds to
25.4Gy with a conventionally EBRT fractionated regimen.
Such dose combined with the further 45–50Gy delivered
postoperatively would reach a total dose of 70–75Gy.
In the Japanese series, patients were treated without RP,
with a potential risk of local recurrence.
The techniques used in the Italian studies are diﬀerent.
Orecchia et al. and Krengli et al. reported complete prostate
removalafterIOERT,whileSaracinoetal.carriedoutIOERT
after retropubic RP. The ﬁrst approach aims to optimize
the irradiated volume including prostate and surrounding
tissuespossiblyinﬁltratedbytumorcells.Itallowsanoptimal
placement of the most appropriate collimator that can vary
in size and bevel angle [14]. Ultrasound measurements of
prostate diameter and distance from the rectal wall can help
in the choice of the most appropriate beam energy and
allows addition of bolus material to modify and optimize
the distribution in depth of the radiation dose when needed.
Using this technique, the dose to the rectum can be limited
because of the interposition of prostate tissue. Finally, this
approach can potentially achieve a better irradiation of the
prostatic apex, which is frequently a site of recurrence. An
important point to underline for any technical approach
is the need of precise documentation in terms of quality
assurance, such as “in vivo” rectal dosimetry and possibly
urethral dosimetry.
Diﬀerent from the Japanese old experience that delivered
a relatively high single dose of 28–35Gy or of 20–25Gy when
combined with EBRT to the target, Saracino et al. used a
single dose up to 22Gy in intermediate-risk patients, while
the other Italian authors used a more conservative approach
deliveringonlypartofthedosebyIOERT(12Gy)andadding
EBRT in patients with positive margins or extracapsular
disease.
A potential critical aspect of this approach is the time
interval between IOERT and EBRT, that is, about 2-3
months. The rationale of this delay is to allow an adequate
recovery of tissues from surgical trauma and to minimize the
risk of persistent urinary incontinence.
RP is performed according to the recommended tech-
nique for locally advanced PC [25]. The additional time
required for IOERT is short, on average 30 minutes [12–
14, 19].
In the Italian IOERT studies there are no signiﬁcant
diﬀerences in terms of surgical complications, early toxicity,
1-year continence rate, and late side eﬀects [12–14, 19].
No major surgical complications were described by all
authors. Rocco et al. reported higher blood loss and need of
transfusion for IOERT patients compared to those treated by
conventionalRP.However,thisdiﬀerencewasnotstatistically
signiﬁcant (42% versus 30%) [19].
IOERT gastrointestinal and genitourinary toxicities are
always low and similar to those of EBRT [26, 27]. In Rocco’s
paper, a comparable toxicity between IOERT + EBRT and
EBRT was also reported [19].
Rectal dosimetry showed a mean dose delivered to the
anterior rectal wall of 3.5Gy with a range of 0.44–7.99
[14, 20]. A relevant dose reduction was constantly observed
at the level of the posterior rectal wall showing that the
rectum was in the steep component of the in-depth dose-
distribution curve.
Several questions still remain unsolved. IOERT is part of
multidisciplinary approaches for high-risk, locally advanced
PC. Therefore, it is diﬃcult to discriminate its contribution
to the oncological outcomes. Furthermore, the published
series are small and with short follow-up and the optimal
IOERT technique is still unclear (IOERT before or after
prostate removal, dose of radiation). Current clinical staging
is not optimal, and a proportion of patients are at risk of
overtreatment when IOERT is delivered (about 1/3 of the
patients in the literature series had negative surgical margins
and pT2 disease).
5. Conclusion
IOERT is safe and feasible with a low complication rate after
short-intermediate follow-up. Combined RP and IOERT
are potentially an eﬀective ﬁrst step in the multimodality
approach for the treatment of high-risk PC. Finally, com-
parative trials are needed to allow a statistically powerful
comparison of IOERT outcomes with those of gold standard
treatments for high-risk PC. Until long-term safety and
oncological results of IOERT are not available, this technique
should be considered an experimental option in the treat-
ment of high-risk PC.
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